Compass Pathways Plc’s shares plummeted after its psychedelic drug to treat a form of depression disappointed investors in a late-stage trial. The company said its psilocybin drug reduced depression ...
Hosted on MSN
This psychedelics stock just keeps getting hotter; why shares bypassed a profit-taking zone
Shares of Compass PathwaysCMPS rallied Monday, briefly bypassing a profit-taking zone, on growing enthusiasm for the company's psilocybin-based approach to treatment-resistant depression. Psilocybin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results